Non-alcoholic fatty liver disease classification: Difference between revisions

	Non-Alcoholic Fatty Liver Disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case studies
Case #1
Non-alcoholic fatty liver disease classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Non-alcoholic fatty liver disease classification
CDC on Non-alcoholic fatty liver disease classification
Non-alcoholic fatty liver disease classification in the news
Blogs on Non-alcoholic fatty liver disease classification
Directions to Hospitals Treating Non-alcoholic fatty liver disease
Risk calculators and risk factors for Non-alcoholic fatty liver disease classification

VisualWikitext

Latest revision as of 13:57, 27 December 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Non-alcoholic fatty liver (NAFLD) disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.

Clinical Classification

Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.^[1]^[2]^[3]

Based on clinical presentation
Non-alcoholic fatty liver	Non-alcoholic steatohepatitis
Benign	Aggressive
Non-progressive	Can progress to cirrhosis Rarely can give rise to hepatocellular carcinoma
Based on Etiology
Primary NAFLD	If the cause of the liver disease was unknown.
Secondary NAFLD	If the cause of the liver disease is secondary to: Surgery for morbid obesity An adverse drug effect Conditions such as abetalipoproteinemia or Wilson’s disease

Histopathological classification

Histological classification of NAFLD includes grading and staging.

Grade: Depending on degree of steatosis and necro-inflammatory activity
Stage: Depending on degree of fibrosis.

Grading

NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for steatosis, lobular inflammation, and ballooning.^[4]

Component	Range	Score
Steatosis	<5%	0
	5-33%	1
	34-66%	2
	>66%	3
Lobular Inflammation	None	0
	<2 focci	1
	2-4	2
	>4	3
Hepatocyte -Balloning	None	0
	Few ballooned cells	1
	Many ballooned cells	2
Interpretation	0-2	Non-diagnostic
	3-4	Borderline
	5-8	Diagnostic

Staging

Based on the degree of fibrosis on biopsy non-alochoic fatty liver disease can be classified into 4 stages.

Staging
Stage 1	Zone 3 fibrosis Perisinusoidal fibrosis Portal/ periportal fibrosis
Stage 2	Perisinusoidal and portal/periportal fibrosis
Stage 3	Bridging fibrosis
Stage 4	Cirrhosis

References

↑ Hashimoto E, Tokushige K, Ludwig J (2015). "Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges". Hepatol Res. 45 (1): 20–8. doi:10.1111/hepr.12333. PMID 24661406.
↑ Cobbina E, Akhlaghi F (2017). "Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters". Drug Metab Rev. 49 (2): 197–211. doi:10.1080/03602532.2017.1293683. PMC 5576152. PMID 28303724.
↑ Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL (2014). "Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease". Anal Cell Pathol (Amst). 2014: 526979. doi:10.1155/2014/526979. PMC 4333905. PMID 25763333.
↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.

Template:WS Template:WH

[pmid24661406-1] Hashimoto E, Tokushige K, Ludwig J (2015). "Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges". Hepatol Res. 45 (1): 20–8. doi:10.1111/hepr.12333. PMID 24661406.

[pmid28303724-2] Cobbina E, Akhlaghi F (2017). "Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters". Drug Metab Rev. 49 (2): 197–211. doi:10.1080/03602532.2017.1293683. PMC 5576152. PMID 28303724.

[pmid25763333-3] Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL (2014). "Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease". Anal Cell Pathol (Amst). 2014: 526979. doi:10.1155/2014/526979. PMC 4333905. PMID 25763333.

[pmid28507929-4] Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.

[1]

[2]

[3]

[4]

@@ Line 4: / Line 4: @@
 ==Overview==
-Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.
+Non-alcoholic fatty liver (NAFLD)  disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.
-==Classification==
+==Clinical Classification==
 Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.<ref name="pmid24661406">{{cite journal| author=Hashimoto E, Tokushige K, Ludwig J| title=Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. | journal=Hepatol Res | year= 2015 | volume= 45 | issue= 1 | pages= 20-8 | pmid=24661406 | doi=10.1111/hepr.12333 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24661406  }} </ref><ref name="pmid28303724">{{cite journal| author=Cobbina E, Akhlaghi F| title=Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. | journal=Drug Metab Rev | year= 2017 | volume= 49 | issue= 2 | pages= 197-211 | pmid=28303724 | doi=10.1080/03602532.2017.1293683 | pmc=5576152 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28303724  }} </ref><ref name="pmid25763333">{{cite journal| author=Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL| title=Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. | journal=Anal Cell Pathol (Amst) | year= 2014 | volume= 2014 | issue=  | pages= 526979 | pmid=25763333 | doi=10.1155/2014/526979 | pmc=4333905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25763333  }} </ref>
 {| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
 ! colspan="2" style="background:#efefef;" |Based on clinical presentation
 |-
-! style="background:#efefef;" |Non-alcoholic fatty aliver
+! style="background:#efefef;" |Non-alcoholic fatty liver
 ! style="background:#efefef;" |Non-alcoholic steatohepatitis
 |-
@@ Line 22: / Line 22: @@
 * Non-progressive
 |
-* Can progress to cirrhosis
+* Can progress to [[cirrhosis]]
-* Rarely can give rise to hepatocellular carcinoma
+* Rarely can give rise to [[hepatocellular carcinoma]]
 |-
-! colspan="2" style="background:#efefef;" |Based on histopathology
+! colspan="2" style="background:#efefef;" |Based on Etiology
 |-
-| colspan="2" |
+|
-* Steatosis
+* Primary NAFLD
+|
+* If the cause of the liver disease was unknown.
 |-
-| colspan="2" |
+|
-* Steatohepatitis
+* Secondary NAFLD
-** Grade: depends on degree of steatosis and necroinflammatory activity
+|
+* If the cause of the liver disease is secondary to:
+** Surgery for [[morbid obesity]]
+** An adverse drug effect
+** Conditions such as [[abetalipoproteinemia]] or [[Wilson's disease|Wilson’s disease]]
+|}
+==Histopathological classification==
+Histological classification of NAFLD includes grading and staging.
+* Grade: Depending on degree of [[steatosis]] and necro-inflammatory activity
+* Stage: Depending on degree of [[fibrosis]].
-** Stage: depends on degree of fibrosis
+===Grading===
-|}
+NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for [[steatosis]], lobular [[inflammation]], and ballooning.<ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
-====NAFLD Activity Score <ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="urlTransplant Pathology Internet Services">{{cite web |url=http://tpis.upmc.com/changebody.cfm?url=/tpis/schema/NAFLD2006.jsp |title=Transplant Pathology Internet Services |format= |work= |accessdate=}}</ref>====
+{| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
-NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for [[steatosis]], lobular [[inflammation]], and ballooning.
+! style="background:#efefef;" |Component
-{| class="wikitable"
+! style="background:#efefef;" |Range
-!Component
+! style="background:#efefef;" |Score
-!Range
-!Score
 |-
 | rowspan="4" |Steatosis
@@ Line 69: / Line 79: @@
 |3
 |-
-| rowspan="3" |Hepatocyte  Balloning
+| rowspan="3" |Hepatocyte -Balloning
 |None
 |0
@@ Line 79: / Line 89: @@
 |2
 |-
-| rowspan="3" |Interpretation
+| rowspan="3" style="background:#efefef;" |Interpretation
-|0-2
+| style="background:#efefef;" |0-2
-|Non-diagnostic
+| style="background:#efefef;" |Non-diagnostic
+|-
+| style="background:#efefef;" |3-4
+| style="background:#efefef;" |Borderline
+|-
+| style="background:#efefef;" |5-8
+| style="background:#efefef;" |Diagnostic
+|}
+===Staging===
+Based on the degree of [[fibrosis]] on [[biopsy]] non-alochoic fatty liver disease can be classified into 4 stages.
+{| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
+! colspan="2" style="background:#efefef;" |Staging
+|-
+|Stage 1
+|
+Zone 3 [[fibrosis]]<br>
+Perisinusoidal [[fibrosis]]<br>
+Portal/ periportal [[fibrosis]]
+|-
+|Stage 2
+|Perisinusoidal and portal/periportal fibrosis
 |-
-|3-4
+|Stage 3
-|Borderline
+|Bridging [[fibrosis]]
 |-
-|5-8
+|Stage 4
-|Diagnostic
+|[[Cirrhosis]]
 |}
 ==References==
 {{reflist|2}}